Keros Therapeutics, Inc. (KROS) Shareholders’ equity 2019–2025
Keros Therapeutics, Inc. (KROS) shareholders’ equity at each fiscal year-end, per SEC filings.
$303.1MFY2025 · since FY2019: -$19.4M → $303.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $303.1M | -47.0% |
| FY2024 | $571.6M | +72.0% |
| FY2023 | $332.2M | +19.7% |
| FY2022 | $277.4M | +14.1% |
| FY2021 | $243.2M | -7.1% |
| FY2020 | $261.7M | +1445.9% |
| FY2019 | -$19.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice